Princeton, NJCIK 13885514 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
11 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Spdr Gold Tr | 7.0K | $2.76M | 64.5% | −322 | Reduced |
| 2 | Berkshire Hathaway Inc Del | 710 | $356.8K | 8.3% | +59 | Added |
| 3 | Spyre Therapeutics Inc | 8.9K | $292.2K | 6.8% | +8.9K | New |
| 4 | Mind Medicine Mindmed Inc |
| 15.7K |
| $210.1K |
| 4.9% |
| −11.3K |
| Reduced |
| 5 | Kyverna Therapeutics Inc | 18.8K | $176.5K | 4.1% | −4.2K | Reduced |
| 6 | Compass Therapeutics Inc | 29.5K | $158.4K | 3.7% | −24.0K | Reduced |
| 7 | Lexeo Therapeutics Inc | 13.9K | $138.5K | 3.2% | −3.4K | Reduced |
| 8 | X4 Pharmaceuticals Inc | 15.6K | $62.2K | 1.5% | +15.6K | New |
| 9 | Inhibikase Therapeutics Inc | 28.5K | $58.3K | 1.4% | +12.1K | Added |
| 10 | Sab Biotherapeutics Inc | 10.5K | $39.4K | 0.9% | −408 | Reduced |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio